rxstat › Shortages › Ondansetron

Ondansetron (Zofran, Ondissolve Odf) shortage status

Partial shortage

Source: Health Canada shortage reports · Updated Oct 16, 2026

Some Ondansetron products are in shortage in Canada (10 of 55 reported products), while others remain available. Your pharmacy may be able to substitute an unaffected manufacturer. The latest estimate for affected products to return is Dec 11, 2026.

An anti-nausea medication used to prevent nausea and vomiting, such as after chemotherapy or surgery.

Products affected
10 / 55
In shortage since
Feb 29, 2016
Est. full return
Dec 11, 2026
Reports on file
151
Talk to a pharmacist
Pharmacists can substitute an unaffected manufacturer's version, adjust strengths, and in most provinces adapt or renew a prescription on the spot.
Book a pharmacist appointment
Need your prescription switched?
If your product stays unavailable, an online doctor can assess your situation and prescribe an alternative.
See a doctor online

Independent services, not affiliated with rxstat; referral fees may apply. Free options exist depending on your province. In an emergency call 911; free health advice at 811.

Shortage history

2023 2024 2025 2026

Shortage history (red bands = periods in shortage).

Reports by product

The DIN is printed on your prescription label.

Active shortage
APO-ONDANSETRON
8MG · TABLET · APOTEX INC
DIN 02288192 · since Sep 8, 2026, est. end Nov 27, 2026 · Disruption of the manufacture of the drug.
Active shortage
APO-ONDANSETRON
8MG · TABLET · APOTEX INC
DIN 02288192 · since Sep 22, 2026, est. end Nov 20, 2026 · Disruption of the manufacture of the drug.
Active shortage
JAMP ONDANSETRON
4MG · SOLUTION · JAMP PHARMA CORPORATION
DIN 02490617 · since ?, est. end Dec 11, 2026 · Disruption of the manufacture of the drug.
Active shortage
JAMP ONDANSETRON ODF
8MG · FILM, SOLUBLE · JAMP PHARMA CORPORATION
DIN 02541378 · since Jun 30, 2026, est. end Sep 25, 2026 · Disruption of the manufacture of the drug.
Active shortage
JAMP ONDANSETRON ODF
4MG · FILM, SOLUBLE · JAMP PHARMA CORPORATION
DIN 02541351 · since Jun 30, 2026, est. end Sep 25, 2026 · Disruption of the manufacture of the drug.
Active shortage
APO-ONDANSETRON
8MG · TABLET · APOTEX INC
DIN 02288192 · since May 4, 2026, est. end Jun 26, 2026 · Disruption of the manufacture of the drug.
Active shortage
APO-ONDANSETRON
8MG · TABLET · APOTEX INC
DIN 02288192 · since May 19, 2026, est. end Jun 26, 2026 · Disruption of the manufacture of the drug.
Active shortage
APO-ONDANSETRON
8MG · TABLET · APOTEX INC
DIN 02288192 · since Jan 13, 2026, est. end Apr 10, 2026 · Disruption of the manufacture of the drug.
Active shortage
APO-ONDANSETRON
4MG · TABLET · APOTEX INC
DIN 02288184 · since Jan 13, 2026, est. end Apr 3, 2026 · Disruption of the manufacture of the drug.
Active shortage
APO-ONDANSETRON
4MG · SOLUTION · APOTEX INC
DIN 02291967 · since Dec 30, 2025, no end estimate · Disruption of the manufacture of the drug.
Active shortage
TEVA-ONDANSETRON
8MG · TABLET · TEVA CANADA LIMITED
DIN 02296357 · since Nov 5, 2025, no end estimate · Disruption of the manufacture of the drug.
Active shortage
TEVA-ONDANSETRON
4MG · TABLET · TEVA CANADA LIMITED
DIN 02296349 · since Nov 5, 2025, no end estimate · Disruption of the manufacture of the drug.

Showing 12 of 60 reports. All reports are on file with Health Canada.

What's happening

Ondansetron is currently affected by 10 active shortage reports filed with Health Canada by APOTEX INC, JAMP PHARMA CORPORATION, TEVA CANADA LIMITED.

The reported cause is: disruption of the manufacture of the drug. Manufacturers must report shortages, but end-date estimates are their own projections and often move.

If your usual product is affected, a pharmacist is the fastest route to a solution: they can dispense an unaffected manufacturer's equivalent when one exists, and in most provinces can adapt doses or substitute a therapeutic alternative without a new appointment.

Ondansetron is classified under “ANTIEMETICS AND ANTINAUSEANTS” (ATC A04AA).

Recent changes

Common questions

What is Ondansetron used for?

An anti-nausea medication used to prevent nausea and vomiting, such as after chemotherapy or surgery.

When will Ondansetron be back in stock in Canada?

The latest manufacturer estimate is Dec 11, 2026. Estimates are self-reported and often slip; this page updates automatically when they change.

Why is Ondansetron in shortage?

See the reports above; manufacturers must state a reason (most commonly manufacturing disruption or a surge in demand) when filing with Health Canada.

What can my pharmacist do about it?

Often quite a lot: substitute an equivalent product from an unaffected manufacturer, adjust quantities, or in most provinces adapt or renew prescriptions on the spot. Call your pharmacy before visiting, and call 811 for free health advice.

Email alerts

Get an email when this drug's status changes. Double opt-in, one-click unsubscribe.

Possible alternatives in the same class (antiemetics and antinauseants)

Drugs in the same therapeutic class, best-supplied first. These are not automatic substitutes: only your pharmacist or prescriber can judge whether a switch makes sense for you.

Nabilone (Cesamet) No current shortage Granisetron Partial shortage 1 of 2 reported products affected Palonosetron (Aloxi) Partial shortage 1 of 2 reported products affected Fosaprepitant (Emend) Shortage anticipated 0 of 1 reported products affected Aprepitant (Emend) Discontinued 0 of 2 reported products affected Aprepitant (Emend Tri-Pack) Discontinued 0 of 1 reported products affected

Guides: what to do when your medication is in shortage · how to read shortage reports

Data reflects reports manufacturers are legally required to file with Health Canada, republished with per-drug aggregation by rxstat. Estimated end dates are supplied by manufacturers and frequently change. This page describes drug supply only and is not medical advice; never stop or switch a medication without speaking to your pharmacist or prescriber.